GPCRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Structure Therapeutics Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$22.01+0.93 (+4.41%)
Close on Oct 19, 2026
- Market cap
- $4.80B
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
31.6%
68M of 214M shares
Institutional holders
192
29 new, 31 sold out
Net institutional buying
6M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Lampert Mark N | 9,611,751 | 5.60% | 13G (passive) | Aug 11, 2025 |
| Janus Henderson Group PLC | 4,448,826 | 7.70% | 13G (passive) amendment | Sep 30, 2025 |
| Abigail P. Johnson | 31,112,634 | 15.00% | 13G (passive) amendment | Dec 31, 2025 |
| FMR LLC | 28,197,369 | 13.20% | 13G (passive) amendment | Jun 30, 2026 |
| Wellington Investment Advisors Holdings LLP | 21,365,952 | 10.10% | 13G (passive) amendment | Dec 31, 2025 |
| Wellington Management Company LLP | 20,631,498 | 11.50% | 13G (passive) amendment | Oct 31, 2025 |
| Avoro Capital Advisors LLC | 16,216,665 | 9.38% | 13G (passive) | Sep 30, 2025 |
| Deep Track Biotechnology Master Fund, Ltd. | 12,647,433 | 7.32% | 13G (passive) amendment | Sep 30, 2025 |
| Deep Track Capital, LP | 12,335,346 | 5.95% | 13G (passive) amendment | Dec 31, 2025 |
| David Kroin | 12,300,000 | 7.15% | 13G (passive) amendment | Mar 31, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of GPCR | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| FMR LLC | 7,810,306 | 3.65% | $419.18M | −593,143 | 0.02% |
| Wellington Management Group Llp | 7,379,433 | 3.45% | $396.05M | +119,146 | 0.07% |
| Avoro Capital Advisors LLC | 6,555,555 | 3.06% | $351.84M | – | 3.16% |
| Jupiter Topco LLC | 5,204,212 | 2.43% | $279.34M | New | 0.11% |
| Deep Track Capital, LP | 4,740,072 | 2.22% | $254.40M | +460,224 | 3.70% |
| Bvf Inc/Il | 3,366,823 | 1.57% | $180.70M | −92,535 | 4.62% |
| Morgan Stanley | 2,806,640 | 1.31% | $150.63M | +501,183 | 0.01% |
| Orbimed Advisors LLC | 2,209,400 | 1.03% | $118.58M | +733,997 | 2.20% |
| Principal Financial Group Inc | 1,752,753 | 0.82% | $94.07M | −1,011 | 0.05% |
| American Century Companies Inc | 1,682,179 | 0.79% | $90.28M | +244,148 | 0.04% |
| Rtw Investments, LP | 1,607,507 | 0.75% | $86.27M | New | 0.74% |
| Driehaus Capital Management LLC | 1,553,219 | 0.73% | $83.36M | −24,137 | 0.48% |
| Baker Bros. Advisors LP | 1,432,529 | 0.67% | $76.88M | – | 0.39% |
| Casdin Capital, LLC | 1,175,000 | 0.55% | $63.06M | – | 3.16% |
| Deerfield Management Company, L.P. (Series C) | 1,086,000 | 0.51% | $58.29M | +318,007 | 0.61% |
| Capitolis Liquid Global Markets LLC | 1,041,100 | 0.49% | $55.88M | −110,200 | 0.24% |
| Siren, L.L.C. | 872,967 | 0.41% | $46.85M | −455,731 | 0.95% |
| Price T Rowe Associates Inc /Md/ | 845,532 | 0.40% | $45.38K | −1,155,164 | 0.00% |
| Pacific Heights Asset Management LLC | 800,000 | 0.37% | $42.94M | +50,000 | 1.36% |
| Rock Springs Capital Management LP | 640,317 | 0.30% | $34.37M | +100 | 1.68% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 192 | 68M | 31.6% | 29 / 76 | 51 / 31 | 12M | 6M |
| Q1 2026 | 196 | 67M | 31.3% | 40 / 73 | 57 / 39 | 8M | 6M |
| Q4 2025 | 197 | 66M | 30.8% | 71 / 52 | 62 / 27 | 20M | 11M |
| Q3 2025 | 156 | 57M | 26.5% | 22 / 57 | 49 / 37 | 13M | 11M |
| Q2 2025 | 172 | 55M | 25.6% | 38 / 63 | 44 / 16 | 9M | 10M |
| Q1 2025 | 150 | 56M | 26.2% | 23 / 47 | 50 / 36 | 4M | 9M |
| Q4 2024 | 164 | 61M | 28.4% | 29 / 64 | 50 / 23 | 8M | 9M |
| Q3 2024 | 160 | 62M | 28.8% | 28 / 68 | 35 / 33 | 9M | 7M |
| Q2 2024 | 166 | 60M | 28.2% | 61 / 63 | 33 / 13 | 23M | 7M |
| Q1 2024 | 119 | 44M | 20.7% | 25 / 45 | 35 / 26 | 9M | 8M |
| Q4 2023 | 121 | 43M | 20.0% | 54 / 36 | 25 / 17 | 19M | 9M |
| Q3 2023 | 84 | 33M | 15.3% | 42 / 29 | 6 / 6 | 17M | 2M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of GPCR | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Health Care Fund | 3,278,237 | 1.53% | $157.49M | 0.41% | Jul 31, 2026 |
| Heritage Fund | 967,353 | 0.45% | $46.47M | 0.87% | Jul 31, 2026 |
| Fidelity Advisor Growth Opportunities Fund | 733,500 | 0.34% | $28.86M | 0.08% | May 31, 2026 |
| Global Emerging Markets Fund | 625,751 | 0.29% | $30.06M | 0.40% | Jul 31, 2026 |
| Janus Henderson Global Life Sciences Fund | 549,353 | 0.26% | $29.48M | 0.51% | Jun 30, 2026 |
| Select Biotechnology Portfolio | 542,038 | 0.25% | $21.32M | 0.40% | May 31, 2026 |
| Select Health Care Portfolio | 540,000 | 0.25% | $21.24M | 0.37% | May 31, 2026 |
| Fidelity Advisor Biotechnology Fund | 527,900 | 0.25% | $25.36M | 1.15% | Jul 31, 2026 |
| Janus Henderson Triton Fund | 467,112 | 0.22% | $25.07M | 0.42% | Jun 30, 2026 |
| Fidelity Stock Selector Small Cap Fund | 433,100 | 0.20% | $20.81M | 0.28% | Jul 31, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 419,407 | 0.20% | $22.51M | 0.19% | Jun 30, 2026 |
| Fidelity Small Cap Growth Fund | 414,389 | 0.19% | $19.91M | 0.23% | Jul 31, 2026 |
| iShares Biotechnology ETF | 414,261 | 0.19% | $22.23M | 0.24% | Jun 30, 2026 |
| Vanguard Explorer Fund | 405,606 | 0.19% | $19.49M | 0.09% | Jul 31, 2026 |
| Permanent Portfolio | 400,000 | 0.19% | $19.22M | 0.27% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Raymond C. Stevens | CHIEF EXECUTIVE OFFICER, Director | 2,956,179 | 1.38% | Mar 23, 2026 |
| Crespo Blas Coll | CHIEF MEDICAL OFFICER | 258,228 | 0.12% | Sep 22, 2026 |
| Xichen Lin | CHIEF SCIENTIFIC OFFICER | 228,960 | 0.11% | Sep 2, 2026 |
| John Joseph Berrios | Chief Commercial Officer | 140,766 | 0.07% | Aug 7, 2026 |
| Matthew Lang | COO & GC | 184,614 | 0.09% | Apr 23, 2026 |
| Jun Yoon | CHIEF FINANCIAL OFFICER | 2,956,242 | 1.38% | Mar 23, 2026 |
| Yingli Ma | CHIEF TECHNOLOGY OFFICER | 139,917 | 0.07% | Mar 23, 2026 |
| Ashley Hall | Chief Development Officer | 155,187 | 0.07% | Mar 23, 2026 |
| Eric Dobmeier | Director | – | – | Jun 18, 2026 |
| Angus C. Russell | Director | – | – | Jun 18, 2026 |
| Ted W. Love | Director | – | – | Jun 18, 2026 |
| Daniel G. Welch | Director | 123,508 | 0.06% | Jun 18, 2026 |
| Sharon Tetlow | Director | – | – | Jun 18, 2026 |
| Joanne Waldstreicher | Director | – | – | Jun 18, 2026 |
| Llc Fmr | 10% owner | 261,777 | 0.12% | Jul 24, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Crespo Blas Coll CHIEF MEDICAL OFFICER | Sep 21, 2026 | Conversion | −12,024 | – | – | 258,228 |
| Crespo Blas Coll CHIEF MEDICAL OFFICER | Sep 18, 2026 | Tax withholding | −10,626 | $11.67 | $124.01K | 270,252 |
| Xichen Lin CHIEF SCIENTIFIC OFFICER | Sep 1, 2026 | Conversion | −17,817 | – | – | 228,960 |
| Xichen Lin CHIEF SCIENTIFIC OFFICER | Sep 1, 2026 | Option exercise | +17,817 | $0.34 | $6.06K | 246,777 |
| Xichen Lin CHIEF SCIENTIFIC OFFICER | Aug 18, 2026 | Option exercise | +11,817 | $0.34 | $4.02K | 240,777 |
| Xichen Lin CHIEF SCIENTIFIC OFFICER | Aug 18, 2026 | Conversion | −11,817 | – | – | 228,960 |
| John Joseph Berrios Chief Commercial Officer | Aug 6, 2026 | Award | +140,766 | – | – | 140,766 |
| Xichen Lin CHIEF SCIENTIFIC OFFICER | Aug 4, 2026 | Conversion | −11,817 | – | – | 228,960 |
| Xichen Lin CHIEF SCIENTIFIC OFFICER | Aug 4, 2026 | Option exercise | +11,817 | $0.34 | $4.02K | 240,777 |
| Xichen Lin CHIEF SCIENTIFIC OFFICER | Jul 14, 2026 | Conversion | −23,634 | – | – | 228,960 |
| Xichen Lin CHIEF SCIENTIFIC OFFICER | Jul 14, 2026 | Option exercise | +23,634 | $0.34 | $8.04K | 252,594 |
| Xichen Lin CHIEF SCIENTIFIC OFFICER | Jun 25, 2026 | Conversion | −23,634 | – | – | 228,960 |
| Xichen Lin CHIEF SCIENTIFIC OFFICER | Jun 25, 2026 | Option exercise | +23,634 | $0.34 | $8.04K | 252,594 |
| Matthew Lang COO & GC | Apr 15, 2026 | Award | +184,614 | – | – | 184,614 |
| Yingli Ma CHIEF TECHNOLOGY OFFICER | Mar 19, 2026 | Award | +32,526 | – | – | 139,917 |
| Xichen Lin CHIEF SCIENTIFIC OFFICER | Mar 19, 2026 | Award | +43,368 | – | – | 228,960 |
| Raymond C. Stevens CHIEF EXECUTIVE OFFICER, Director | Mar 19, 2026 | Award | +260,217 | – | – | 1,401,593 |
| Crespo Blas Coll CHIEF MEDICAL OFFICER | Mar 19, 2026 | Award | +75,897 | – | – | 280,878 |
| Ashley Hall Chief Development Officer | Mar 19, 2026 | Award | +47,706 | – | – | 155,187 |
| Jun Yoon CHIEF FINANCIAL OFFICER | Mar 19, 2026 | Award | +104,085 | – | – | 1,401,656 |
| Raymond C. Stevens CHIEF EXECUTIVE OFFICER, Director | Mar 3, 2026 | Tax withholding | −53,454 | $20.99 | $1.12M | 1,141,376 |
| Xichen Lin CHIEF SCIENTIFIC OFFICER | Mar 3, 2026 | Tax withholding | −18,735 | $20.99 | $393.25K | 185,592 |
| Jun Yoon CHIEF FINANCIAL OFFICER | Mar 3, 2026 | Tax withholding | −22,305 | $20.99 | $468.18K | 1,297,571 |
| Crespo Blas Coll CHIEF MEDICAL OFFICER | Mar 3, 2026 | Tax withholding | −11,826 | $20.99 | $248.23K | 204,981 |
| Ashley Hall Chief Development Officer | Mar 3, 2026 | Tax withholding | −4,836 | $20.99 | $101.51K | 107,481 |
| Yingli Ma CHIEF TECHNOLOGY OFFICER | Mar 3, 2026 | Tax withholding | −11,313 | $20.99 | $237.46K | 107,391 |
| Crespo Blas Coll CHIEF MEDICAL OFFICER | Sep 18, 2025 | Tax withholding | −8,106 | $7.74 | $62.74K | 216,807 |
| Ashley Hall Chief Development Officer | Sep 18, 2025 | Tax withholding | −6,021 | $7.74 | $46.60K | 112,317 |
| Yingli Ma CHIEF TECHNOLOGY OFFICER | Jul 1, 2025 | Tax withholding | −4,470 | $6.84 | $30.57K | 118,704 |
| Xichen Lin CHIEF SCIENTIFIC OFFICER | Jul 1, 2025 | Tax withholding | −12,846 | $6.84 | $87.87K | 204,327 |
| Yingli Ma CHIEF TECHNOLOGY OFFICER | Jul 1, 2025 | Award | +24,459 | – | – | 123,174 |
| Crespo Blas Coll CHIEF MEDICAL OFFICER | Jul 1, 2025 | Tax withholding | −1,434 | $6.84 | $9.81K | 224,913 |
| Crespo Blas Coll CHIEF MEDICAL OFFICER | Jul 1, 2025 | Award | +7,992 | – | – | 226,347 |
| Xichen Lin CHIEF SCIENTIFIC OFFICER | Jul 1, 2025 | Award | +57,078 | – | – | 217,173 |
| Raymond C. Stevens CHIEF EXECUTIVE OFFICER, Director | Jul 1, 2025 | Award | +89,697 | – | – | 1,210,880 |
| Raymond C. Stevens CHIEF EXECUTIVE OFFICER, Director | Jul 1, 2025 | Tax withholding | −16,050 | $6.84 | $109.78K | 1,194,830 |
| Jun Yoon CHIEF FINANCIAL OFFICER | Jul 1, 2025 | Tax withholding | −7,089 | $6.84 | $48.49K | 1,319,876 |
| Jun Yoon CHIEF FINANCIAL OFFICER | Jul 1, 2025 | Award | +39,606 | – | – | 1,326,965 |
| Ashley Hall Chief Development Officer | Mar 15, 2025 | Award | +51,048 | – | – | 118,338 |
| Raymond C. Stevens CHIEF EXECUTIVE OFFICER, Director | Mar 15, 2025 | Award | +340,332 | – | – | 1,133,678 |
| Yingli Ma CHIEF TECHNOLOGY OFFICER | Mar 15, 2025 | Award | +63,810 | – | – | 100,539 |
| Crespo Blas Coll Chief Medical Officer | Mar 15, 2025 | Award | +116,988 | – | – | 219,588 |
| Xichen Lin CHIEF SCIENTIFIC OFFICER | Mar 15, 2025 | Award | +80,829 | – | – | 166,536 |
| Jun Yoon CHIEF FINANCIAL OFFICER | Mar 15, 2025 | Award | +170,166 | – | – | 1,293,299 |
| Yingli Ma CHIEF TECHNOLOGY OFFICER | Mar 1, 2025 | Tax withholding | −1,824 | $7.92 | $14.45K | 98,715 |
| Crespo Blas Coll CHIEF MEDICAL OFFICER | Mar 1, 2025 | Tax withholding | −1,233 | $7.92 | $9.77K | 218,355 |
| Xichen Lin CHIEF SCIENTIFIC OFFICER | Mar 1, 2025 | Tax withholding | −6,441 | $7.92 | $51.01K | 160,095 |
| Raymond C. Stevens CHIEF EXECUTIVE OFFICER, Director | Mar 1, 2025 | Tax withholding | −12,495 | $7.92 | $98.96K | 1,121,183 |
| Jun Yoon CHIEF FINANCIAL OFFICER | Mar 1, 2025 | Tax withholding | −5,940 | $7.92 | $47.04K | 1,287,359 |
| Crespo Blas Coll Chief Medical Officer | Sep 18, 2024 | Award | +90,600 | – | – | 102,600 |
| Ashley Hall Chief Development Officer | Sep 18, 2024 | Award | +67,290 | – | – | 67,290 |
| Raymond C. Stevens CHIEF EXECUTIVE OFFICER, Director | Jun 12, 2024 | Option exercise | +99,999 | $0.39 | $39.00K | 743,345 |
| Raymond C. Stevens CHIEF EXECUTIVE OFFICER, Director | Jun 12, 2024 | Option exercise | +50,001 | $0.48 | $24.00K | 793,346 |
| Raymond C. Stevens CHIEF EXECUTIVE OFFICER, Director | Jun 10, 2024 | Conversion | −555,000 | – | – | 643,346 |
| Xichen Lin CHIEF SCIENTIFIC OFFICER | Jun 3, 2024 | Conversion | −106,200 | – | – | 85,707 |
| Xichen Lin CHIEF SCIENTIFIC OFFICER | Jun 3, 2024 | Option exercise | +106,200 | $0.34 | $36.11K | 191,907 |
| Mark Allen Bach CHIEF MEDICAL OFFICER | Mar 15, 2024 | Award | +26,235 | – | – | 26,235 |
| Raymond C. Stevens CHIEF EXECUTIVE OFFICER, Director | Mar 15, 2024 | Award | +134,682 | – | – | 1,198,346 |
| Xichen Lin CHIEF SCIENTIFIC OFFICER | Mar 15, 2024 | Award | +85,707 | – | – | 85,707 |
| Jun Yoon CHIEF FINANCIAL OFFICER | Mar 15, 2024 | Award | +59,469 | – | – | 1,123,133 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Coll Crespo Blas Officer | Sep 21, 2026 | 4,008 | $140.28K | Sep 21, 2026 | Restricted Stock Units |
| Lin Xichen Officer | Jun 25, 2026 | 35,512 | $1.71M | Jun 25, 2026 | Exercise of Stock Options |
| C. Stevens Raymond Officer | Jun 10, 2024 | 185,000 | $9.77M | Jun 10, 2024 | Founder Stock |
| Lin Xichen Officer | Jun 3, 2024 | 59,000 | $2.02M | Jun 3, 2024 | Exercise of Stock Options |